Cross-talk of membrane lipids and Alzheimer-related proteins

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Walter, Jochen ^a,b   Van Echten Deckert, Gerhild ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Europ Grad Sch Neurosci (EURON)   (Germany)

Author keywords

Alzheimer's disease; Beta amyloid; Cholesterol; Gangliosides; Lysosomal storage disorders; Sphingolipids; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; FARNESYL DIPHOSPHATE; GAMMA SECRETASE; GANGLIOSIDE GM1; GERANYLGERANYL PYROPHOSPHATE; GLYCEROPHOSPHOLIPID; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEMBRANE LIPID; MICROTUBULE ASSOCIATED PROTEIN 2; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE C; PRESENILIN; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BRAIN REGION; CELL METABOLISM; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CONFORMATIONAL TRANSITION; DEMENTIA; DISEASE COURSE; ENDOPLASMIC RETICULUM; GENE DELETION; GENE MUTATION; HUMAN; INTERNALIZATION; LIPID METABOLISM; MEMBRANE FLUIDITY; MOLECULAR INTERACTION; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SECRETORY PATHWAY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; HUMANS; MEMBRANE LIPIDS; MEMBRANE PROTEINS; RECEPTOR CROSS-TALK; TAU PROTEINS;

EID: 84886874221     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-34     Document Type: Review

References (144)

1. Alzheimer's disease: genes, proteins, and therapy. Selkoe DJ, Physiol Rev 2001 81 741 766 11274343 (Pubitemid 32267077)
2. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Perrin RJ, Fagan AM, Holtzman DM, Nature 2009 461 916 922 10.1038/nature08538 19829371
3. Tau pathophysiology in neurodegeneration: a tangled issue. Spires-Jones TL, Stoothoff WH, De Calignon A, Jones PB, Hyman BT, Trends Neurosci 2009 32 150 159 10.1016/j.tins.2008.11.007 19162340
4. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Tanzi RE, Bertram L, Cell 2005 120 545 555 10.1016/j.cell.2005.02. 008 15734686 (Pubitemid 40269768)
5. Molecular biology and genetics of Alzheimer's disease. St George-Hyslop PH, Petit A, C R Biol 2005 328 119 130 10.1016/j.crvi.2004.10.013 15770998 (Pubitemid 40247057)
6. The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Kennedy JL, Farrer LA, Andreasen NC, Mayeux R, St George-Hyslop P, Science 2003 302 822 826 10.1126/science.1092132 14593167 (Pubitemid 37339615)
7. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Guerreiro RJ, Gustafson DR, Hardy J, Neurobiol Aging 2012 33 437 456 10.1016/j.neurobiolaging.2010.03.025 20594621
8. Sphingolipids: critical players in Alzheimer's disease. Van Echten-Deckert G, Walter J, Prog Lipid Res 2012 51 378 393 10.1016/j.plipres. 2012.07.001 22835784
9. Autophagy in the pathogenesis of disease. Levine B, Kroemer G, Cell 2008 132 27 42 10.1016/j.cell.2007.12.018 18191218
10. The insulin paradox: aging, proteotoxicity and neurodegeneration. Cohen E, Dillin A, Nat Rev Neurosci 2008 9 759 767 18769445
11. Homeostatic disinhibition in the aging brain and Alzheimer's disease. Gleichmann M, Chow VW, Mattson MP, J Alzheimers Dis 2011 24 15 24 21187584
12. Neural mechanisms of ageing and cognitive decline. Bishop NA, Lu T, Yankner BA, Nature 2010 464 529 535 10.1038/nature08983 20336135
13. Apolipoprotein E and Alzheimer's disease. Strittmatter WJ, Roses AD, Annu Rev Neurosci 1996 19 53 77 10.1146/annurev.ne.19.030196.000413 8833436 (Pubitemid 26080822)
14. The genetics of Alzheimer disease: back to the future. Bertram L, Lill CM, Tanzi RE, Neuron 2010 68 270 281 10.1016/j.neuron.2010.10.013 20955934
15. The role of apolipoprotein E in Alzheimer's disease. Kim J, Basak JM, Holtzman DM, Neuron 2009 63 287 303 10.1016/j.neuron.2009.06.026 19679070
16. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Dietschy JM, Biol Chem 2009 390 287 293 19166320
17. Gamma-Secretase, apolipoprotein E and Cellular cholesterol metabolism. Walter J, Curr Alzheimer Res 2012 9 189 199 10.2174/156720512799361583 21605030
18. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM, Proc Natl Acad Sci U S A 2013 110 1807 E1816 10.1073/pnas.1220484110 23620513
19. Neurodegenerative lysosomal disorders: a continuum from development to late age. Nixon RA, Yang DS, Lee JH, Autophagy 2008 4 590 599 18497567
20. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K, Cell 1989 57 115 126 10.1016/0092-8674(89)90177-3 2649245 (Pubitemid 19098873)
21. Phosphorylation of the beta-amyloid precursor protein at the cell surface by ectocasein kinases 1 and 2. Walter J, Schindzielorz A, Hartung B, Haass C, J Biol Chem 2000 275 23523 23529 10.1074/jbc.M002850200 10806211 (Pubitemid 30624634)
22. The gamma-secretase complex: machinery for intramembrane proteolysis. Iwatsubo T, Curr Opin Neurobiol 2004 14 379 383 10.1016/j.conb.2004.05.010 15194119 (Pubitemid 38759869)
23. Intramembrane proteolysis by gamma-secretase. Steiner H, Fluhrer R, Haass C, J Biol Chem 2008 283 29627 29631 10.1074/jbc.R800010200 18650432
24. Building gamma-secretase: the bits and pieces. Spasic D, Annaert W, J Cell Sci 2008 121 413 420 10.1242/jcs.015255 18256384 (Pubitemid 351405049)
25. Presenilin: running with scissors in the membrane. Selkoe DJ, Wolfe MS, Cell 2007 131 215 221 10.1016/j.cell.2007.10.012 17956719 (Pubitemid 47576152)
26. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. De Strooper B, Annaert W, Annu Rev Cell Dev Biol 2010 26 235 260 10.1146/annurev-cellbio-100109-104117 20604710
27. Amyloid precursor protein trafficking, processing, and function. Thinakaran G, Koo EH, J Biol Chem 2008 283 29615 29619 10.1074/jbc.R800019200 18650430
28. Identification and biology of beta-secretase. Kandalepas PC, Vassar R, J Neurochem 2012 120 Suppl 1 55 61 22122287
29. Ectodomain shedding and ADAMs in development. Weber S, Saftig P, Development 2012 139 3693 3709 10.1242/dev.076398 22991436
30. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ, Nature 1992 357 500 503 10.1038/357500a0 1608449
31. Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein. Nunan J, Williamson NA, Hill AF, Sernee MF, Masters CL, Small DH, J Neurosci Res 2003 74 378 385 10.1002/jnr.10646 14598314 (Pubitemid 37362814)
32. Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation. Tamboli IY, Hampel H, Tien NT, Tolksdorf K, Breiden B, Mathews PM, Saftig P, Sandhoff K, Walter J, J Neurosci 2011 31 1837 1849 10.1523/JNEUROSCI.2954-10.2011 21289194
33. Sphingolipid storage impairs autophagic clearance of Alzheimer-associated proteins. Tamboli IY, Tien NT, Walter J, Autophagy 2011 7 645 646 10.4161/auto.7.6.15122 21460623
34. Amyloid-beta secretion, generation, and lysosomal sequestration in response to proteasome inhibition: involvement of autophagy. Agholme L, Hallbeck M, Benedikz E, Marcusson J, Kagedal K, J Alzheimers Dis 2012 31 343 358 22555375
35. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, Martins RN, Mol Psychiatry 2009 14 469 486 10.1038/mp.2008.96 18794889
36. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA, J Neurochem 2010 115 1077 1089 10.1111/j.1471-4159.2010.07002.x 20854368
37. Proteolytic degradation of amyloid beta-protein. Saido T, Leissring MA, Cold Spring Harb Perspect Med 2012 2 006379 10.1101/cshperspect.a006379 22675659
38. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ, J Neurochem 2012 120 Suppl 1 167 185 22122230
39. Cholesterol metabolism in the brain. Dietschy JM, Turley SD, Curr Opin Lipidol 2001 12 105 112 10.1097/00041433-200104000-00003 11264981 (Pubitemid 32242918)
40. Sphingolipid metabolism in neural cells. Van Echten-Deckert G, Herget T, Biochim Biophys Acta 2006 1758 1978 1994 10.1016/j.bbamem.2006.06.009 16843432 (Pubitemid 44879360)
41. Lipids in Alzheimer's disease and their potential for therapy. Lütjohann D, Meichsner S, Pettersson H, Clin Lipidol 2012 7 65 78 10.2217/clp.11.74
42. Deregulation of sphingolipid metabolism in Alzheimer's disease. He X, Huang Y, Li B, Gong CX, Schuchman EH, Neurobiol Aging 2010 31 398 408 10.1016/j.neurobiolaging.2008.05.010 18547682
43. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Haughey NJ, Bandaru VV, Bae M, Mattson MP, Biochim Biophys Acta 1801 2010 878 886
44. Regional membrane phospholipid alterations in Alzheimer's disease. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR, Neurochem Res 1998 23 81 88 10.1023/A:1022457605436 9482271 (Pubitemid 28145695)
45. Phospholipids and Alzheimer's disease: alterations, mechanisms and potential biomarkers. Kosicek M, Hecimovic S, Int J Mol Sci 2013 14 1310 1322 10.3390/ijms14011310 23306153
46. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. Ehehalt R, Keller P, Haass C, Thiele C, Simons K, J Cell Biol 2003 160 113 123 10.1083/jcb.200207113 12515826 (Pubitemid 36091721)
47. Alzheimer's disease: the lipid connection. Hartmann T, Kuchenbecker J, Grimm MO, J Neurochem 2007 103 Suppl 1 159 170 17986151
48. Ceramide and cholesterol: possible connections between normal aging of the brain and Alzheimer's disease: just hypotheses or molecular pathways to be identified? Costantini C, Kolasani RM, Puglielli L, Alzheimers Dement 2005 1 43 50 10.1016/j.jalz.2005.06.004 19595816 (Pubitemid 43348854)
49. A detergent-insoluble membrane compartment contains A beta in vivo. Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT Jr, Kosik KS, Nat Med 1998 4 730 734 10.1038/nm0698-730 9623986 (Pubitemid 28274677)
50. Cholesterol and Alzheimer's disease: is there a link? Simons M, Keller P, Dichgans J, Schulz JB, Neurology 2001 57 1089 1093 10.1212/WNL.57.6.1089 11571339 (Pubitemid 32880208)
51. Active gamma-secretase is localized to detergent-resistant membranes in human brain. Hur JY, Welander H, Behbahani H, Aoki M, Franberg J, Winblad B, Frykman S, Tjernberg LO, Febs J 2008 275 1174 1187 10.1111/j.1742-4658.2008. 06278.x 18266764 (Pubitemid 351342213)
52. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE, Neurobiol Dis 2002 9 11 23 10.1006/nbdi.2001.0470 11848681 (Pubitemid 34174561)
53. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K, Proc Natl Acad Sci U S A 1998 95 6460 6464 10.1073/pnas.95.11.6460 9600988 (Pubitemid 28249035)
54. Neuronal membrane cholesterol loss enhances amyloid peptide generation. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG, J Cell Biol 2004 167 953 960 10.1083/jcb.200404149 15583033 (Pubitemid 39628117)
55. Amyloid excess in Alzheimer's disease: what is cholesterol to be blamed for? Ledesma MD, Dotti CG, FEBS Lett 2006 580 5525 5532 10.1016/j.febslet.2006. 06.038 16814780 (Pubitemid 44465895)
56. Lipid rafts: linking alzheimer's amyloid-beta production, aggregation, and toxicity at neuronal membranes. Rushworth JV, Hooper NM, Int J Alzheimers Dis 2010 2011 603052 21234417
57. Membrane rafts in Alzheimer's disease beta-amyloid production. Vetrivel KS, Thinakaran G, Biochim Biophys Acta 1801 2010 860 867
58. Linking lipids to Alzheimer's disease: cholesterol and beyond. Di Paolo G, Kim TW, Nat Rev Neurosci 2011 12 284 296 10.1038/nrn3012 21448224
59. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Sisodia SS, Thinakaran G, J Biol Chem 2005 280 25892 25900 10.1074/jbc. M503570200 15886206 (Pubitemid 40962301)
60. The involvement of lipid rafts in Alzheimer's disease. Cordy JM, Hooper NM, Turner AJ, Mol Membr Biol 2006 23 111 122 10.1080/09687860500496417 16611586
61. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, Beel AJ, Sanders CR, Science 2012 336 1168 1171 10.1126/science.1219988 22654059
62. Steroids as gamma-secretase modulators. Jung JI, Ladd TB, Kukar T, Price AR, Moore BD, Koo EH, Golde TE, Felsenstein KM, Faseb J 2013 27 3775 3785 10.1096/fj.12-225649 23716494
63. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ, Proc Natl Acad Sci U S A 2003 100 11735 11740 10.1073/pnas.1635130100 14504402 (Pubitemid 37206004)
64. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM, Nat Cell Biol 2001 3 905 912 10.1038/ncb1001-905 11584272 (Pubitemid 32952255)
65. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM, Neuron 2004 44 227 238 10.1016/j.neuron.2004.08.043 15473963 (Pubitemid 39346248)
66. Cholesterol, statins and tau. Ohm TG, Meske V, Acta Neurol Scand Suppl 2006 185 93 101 16866917 (Pubitemid 44015231)
67. Cholesterol in Alzheimer's disease and tauopathy. Burns M, Duff K, Ann N Y Acad Sci 2002 977 367 375 10.1111/j.1749-6632.2002.tb04839.x 12480774 (Pubitemid 35418177)
68. Neurofibrillary tangles in Niemann-Pick disease type C. Love S, Bridges LR, Case CP, Brain 1995 118 119 129 10.1093/brain/118.1.119 7894998
69. Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain. Distl R, Treiber-Held S, Albert F, Meske V, Harzer K, Ohm TG, J Pathol 2003 200 104 111 10.1002/path.1320 12692848 (Pubitemid 36592643)
70. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Jin LW, Shie FS, Maezawa I, Vincent I, Bird T, Am J Pathol 2004 164 975 985 10.1016/S0002-9440(10)63185-9 14982851 (Pubitemid 38235479)
71. Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. Nixon RA, Am J Pathol 2004 164 757 761 10.1016/S0002-9440(10)63163-X 14982829 (Pubitemid 38235457)
72. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, Wang L, Mathews PM, Noble W, Matsuoka Y, Duff K, J Neurosci 2003 23 5645 5649 12843267 (Pubitemid 36807842)
73. Promotion of tau phosphorylation by MAP kinase Erk1/2 is accompanied by reduced cholesterol level in detergent-insoluble membrane fraction in Niemann-Pick C1-deficient cells. Sawamura N, Gong JS, Chang TY, Yanagisawa K, Michikawa M, J Neurochem 2003 84 1086 1096 10.1046/j.1471-4159.2003.01596.x 12603832 (Pubitemid 36330661)
74. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. Bu B, Li J, Davies P, Vincent I, J Neurosci 2002 22 6515 6525 12151531 (Pubitemid 35386408)
75. Increased tau phosphorylation and impaired brain insulin/igf signaling in mice fed a high fat/high cholesterol diet. Bhat NR, Thirumangalakudi L, J Alzheimers Dis 2013 36 781 789 23703152
76. Dietary cholesterol and its effect on tau protein: a study in apolipoprotein E-deficient and P301L human tau mice. Glockner F, Meske V, Lutjohann D, Ohm TG, J Neuropathol Exp Neurol 2011 70 292 301 10.1097/NEN.0b013e318212f185 21412171
77. Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis. Pacheco CD, Elrick MJ, Lieberman AP, Hum Mol Genet 2009 18 956 965 19074461
78. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S, PLoS Med 2005 2 18 10.1371/journal.pmed.0020018 15647781 (Pubitemid 40412736)
79. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Meske V, Albert F, Richter D, Schwarze J, Ohm TG, Eur J Neurosci 2003 17 93 102 10.1046/j.1460-9568.2003.02433.x 12534972 (Pubitemid 36098879)
80. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Hamano T, Yen SH, Gendron T, Ko LW, Kuriyama M, Neurobiol Aging 2012 33 2306 2320 10.1016/j.neurobiolaging.2011.10.020 22133277
81. Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease. Li L, Zhang W, Cheng S, Cao D, Parent M, Mol Neurobiol 2012 46 64 77 10.1007/s12035-012-8253-1 22418893
82. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: the Rotterdam study. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM, J Neurol Neurosurg Psychiatry 2009 80 13 17 10.1136/jnnp.2008.150433 18931004
83. Cholesterol level and statin use in Alzheimer disease: II: review of human trials and recommendations. Shepardson NE, Shankar GM, Selkoe DJ, Arch Neurol 2011 68 1385 1392 10.1001/archneurol.2011.242 22084122
84. Cholesterol, statins and dementia. Wolozin B, Curr Opin Lipidol 2004 15 667 672 10.1097/00041433-200412000-00007 15529026 (Pubitemid 39612985)
85. Isoprenoids, small GTPases and Alzheimer's disease. Hooff GP, Wood WG, Muller WE, Eckert GP, Biochim Biophys Acta 1801 2010 896 905
86. Isoprenoids and Alzheimer's disease: a complex relationship. Cole SL, Vassar R, Neurobiol Dis 2006 22 209 222 10.1016/j.nbd.2005.11.007 16406223
87. Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. Tamboli IY, Barth E, Christian L, Siepmann M, Kumar S, Singh S, Tolksdorf K, Heneka MT, Lutjohann D, Wunderlich P, Walter J, J Biol Chem 2010 285 37405 37414 10.1074/jbc.M110.149468 20876579
88. Statins in unconventional secretion of insulin-degrading enzyme and degradation of the amyloid-beta peptide. Glebov K, Walter J, Neurodegener Dis 2011 10 309 312 22205103
89. Revitalizing membrane rafts: new tools and insights. Simons K, Gerl MJ, Nat Rev Mol Cell Biol 2010 11 688 699 10.1038/nrm2977 20861879
90. Principles of bioactive lipid signalling: lessons from sphingolipids. Hannun YA, Obeid LM, Nat Rev Mol Cell Biol 2008 9 139 150 10.1038/nrm2329 18216770 (Pubitemid 351158911)
91. Ceramide: an intracellular signal for apoptosis. Hannun YA, Obeid LM, Trends Biochem Sci 1995 20 73 77 10.1016/S0968-0004(00)88961-6 7701566
92. Ceramide sphingolipid signaling mediates tumor necrosis factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. Martinez TN, Chen X, Bandyopadhyay S, Merrill AH, Tansey MG, Mol Neurodegener 2012 7 45 10.1186/1750-1326-7-45 22973882
93. Ceramide function in the brain: when a slight tilt is enough. Mencarelli C, Martinez-Martinez P, Cell Mol Life Sci 2012 70 181 203 22729185
94. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM, J Biol Chem 2003 278 19777 19783 10.1074/jbc.M300466200 12649271 (Pubitemid 36799164)
95. Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. Tamboli IY, Prager K, Barth E, Heneka M, Sandhoff K, Walter J, J Biol Chem 2005 280 28110 28117 10.1074/jbc.M414525200 15923191 (Pubitemid 41076929)
96. Modulation of amyloid precursor protein processing by synthetic ceramide analogues. Li H, Kim WS, Guillemin GJ, Hill AF, Evin G, Garner B, Biochim Biophys Acta 1801 2010 887 895
97. Modulation of amyloid precursor protein cleavage by cellular sphingolipids. Sawamura N, Ko M, Yu W, Zou K, Hanada K, Suzuki T, Gong JS, Yanagisawa K, Michikawa M, J Biol Chem 2004 279 11984 11991 10.1074/jbc. M309832200 14715666 (Pubitemid 38401704)
98. GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Zha Q, Ruan Y, Hartmann T, Beyreuther K, Zhang D, Mol Psychiatry 2004 9 946 952 10.1038/sj.mp.4001509 15052275 (Pubitemid 39381958)
99. Ceramide selectively decreases tau levels in differentiated PC12 cells through modulation of calpain I. Xie H, Johnson GV, J Neurochem 1997 69 1020 1030 9282924 (Pubitemid 27364822)
100. The ganglioside GM1 enhances microtubule networks and changes the morphology of Neuro-2a cells in vitro by altering the distribution of MAP2. Wang LJ, Colella R, Yorke G, Roisen FJ, Exp Neurol 1996 139 1 11 10.1006/exnr.1996.0074 8635555 (Pubitemid 26160371)
101. Ganglioside-enhanced neurite growth: evidence for a selective induction of high-molecular-weight MAP-2. Ferreira A, Busciglio J, Landa C, Caceres A, J Neurosci 1990 10 293 302 2153774 (Pubitemid 20059265)
102. Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. Boland B, Smith DA, Mooney D, Jung SS, Walsh DM, Platt FM, J Biol Chem 2010 285 37415 37426 10.1074/jbc.M110.186411 20864542
103. Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects. Pacheco CD, Kunkel R, Lieberman AP, Hum Mol Genet 2007 16 1495 1503 10.1093/hmg/ddm100 17468177 (Pubitemid 47055121)
104. Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Bernardo A, Harrison FE, McCord M, Zhao J, Bruchey A, Davies SS, Jackson Roberts L, Mathews PM II, Matsuoka Y, Ariga T, Yu RK, Thompson R, McDonald MP, Neurobiol Aging 2009 30 1777 1791 10.1016/j.neurobiolaging.2007.12.022 18258340
105. Gangliosides determine the amyloid pathology of Alzheimer's disease. Oikawa N, Yamaguchi H, Ogino K, Taki T, Yuyama K, Yamamoto N, Shin RW, Furukawa K, Yanagisawa K, Neuroreport 2009 20 1043 1046 19590389
106. Chromatographic separation of human brain gangliosides. Svennerholm L, J Neurochem 1963 10 613 623 10.1111/j.1471-4159.1963.tb08933.x 14066623
107. BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. Takasugi N, Sasaki T, Suzuki K, Osawa S, Isshiki H, Hori Y, Shimada N, Higo T, Yokoshima S, Fukuyama T, Lee VM, Trojanowski JQ, Tomita T, Iwatsubo T, J Neurosci 2011 31 6850 6857 10.1523/JNEUROSCI.6467-10.2011 21543615
108. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K, J Biol Chem 2005 280 36815 36823 10.1074/jbc.M504484200 16115865 (Pubitemid 41587762)
109. Sphingosine-1-phosphate links glycosphingolipid metabolism to neurodegeneration via a calpain-mediated mechanism. Hagen N, Hans M, Hartmann D, Swandulla D, Van Echten-Deckert G, Cell Death Differ 2011 18 1356 1365 10.1038/cdd.2011.7 21331079
110. Direct and potent regulation of gamma-secretase by its lipid microenvironment. Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ, J Biol Chem 2008 283 22529 22540 10.1074/jbc.M801925200 18539594
111. Effects of membrane lipids on the activity and processivity of purified gamma-secretase. Holmes O, Paturi S, Ye W, Wolfe MS, Selkoe DJ, Biochemistry 2012 51 3565 3575 10.1021/bi300303g 22489600
112. Ganglioside GM1 binding the N-terminus of amyloid precursor protein. Zhang H, Ding J, Tian W, Wang L, Huang L, Ruan Y, Lu T, Sha Y, Zhang D, Neurobiol Aging 2009 30 1245 1253 10.1016/j.neurobiolaging.2007.11.013 18077059
113. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Yanagisawa K, Odaka A, Suzuki N, Ihara Y, Nat Med 1995 1 1062 1066 10.1038/nm1095-1062 7489364
114. Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. Mizuno T, Nakata M, Naiki H, Michikawa M, Wang R, Haass C, Yanagisawa K, J Biol Chem 1999 274 15110 15114 10.1074/jbc.274.21.15110 10329717 (Pubitemid 29265901)
115. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K, J Biol Chem 2001 276 24985 24990 10.1074/jbc.M100252200 11342534
116. Abeta polymerization through interaction with membrane gangliosides. Matsuzaki K, Kato K, Yanagisawa K, Biochim Biophys Acta 1801 2010 868 877
117. A seed for Alzheimer amyloid in the brain. Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M, Yamamoto N, Michikawa M, Yoshikawa Y, Terao K, Matsuzaki K, Lemere CA, Selkoe DJ, Naiki H, Yanagisawa K, J Neurosci 2004 24 4894 4902 10.1523/JNEUROSCI.0861-04.2004 15152051 (Pubitemid 38668215)
118. Accelerated Abeta aggregation in the presence of GM1-ganglioside- accumulated synaptosomes of aged apoE4-knock-in mouse brain. Yamamoto N, Igbabvoa U, Shimada Y, Ohno-Iwashita Y, Kobayashi M, Wood WG, Fujita SC, Yanagisawa K, FEBS Lett 2004 569 135 139 10.1016/j.febslet.2004.05.037 15225622 (Pubitemid 38844606)
119. Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid beta-protein fibrillogenesis. Yamamoto N, Matsubara T, Sato T, Yanagisawa K, Biochim Biophys Acta 2008 1778 2717 2726 10.1016/j.bbamem.2008.07.028 18727916
120. Endosomal accumulation of GM1 ganglioside-bound amyloid beta-protein in neurons of aged monkey brains. Kimura N, Yanagisawa K, Neuroreport 2007 18 1669 1673 10.1097/WNR.0b013e3282f0d2ab 17921865 (Pubitemid 47549131)
121. Amyloid precursor protein (APP) mediated regulation of ganglioside homeostasis linking Alzheimer's disease pathology with ganglioside metabolism. Grimm MO, Zinser EG, Grosgen S, Hundsdorfer B, Rothhaar TL, Burg VK, Kaestner L, Bayer TA, Lipp P, Muller U, Grimm HS, Hartmann T, PLoS One 2012 7 34095 10.1371/journal.pone.0034095 22470521
122. Phospholipase C is a key enzyme regulating intracellular calcium and modulating the phosphoinositide balance. Fukami K, Inanobe S, Kanemaru K, Nakamura Y, Prog Lipid Res 2010 49 429 437 10.1016/j.plipres.2010.06.001 20553968
123. Phosphoinositides in cell regulation and membrane dynamics. Di Paolo G, De Camilli P, Nature 2006 443 651 657 10.1038/nature05185 17035995 (Pubitemid 44564702)
124. Understanding of the roles of phospholipase D and phosphatidic acid through their binding partners. Jang JH, Lee CS, Hwang D, Ryu SH, Prog Lipid Res 2012 51 71 81 10.1016/j.plipres.2011.12.003 22212660
125. Generation of Alzheimer disease-associated amyloid beta42/43 peptide by gamma-secretase can be inhibited directly by modulation of membrane thickness. Winkler E, Kamp F, Scheuring J, Ebke A, Fukumori A, Steiner H, J Biol Chem 2012 287 21326 21334 10.1074/jbc.M112.356659 22532566
126. Phosphoinositides suppress gamma-secretase in both the detergent-soluble and -insoluble states. Osawa S, Funamoto S, Nobuhara M, Wada-Kakuda S, Shimojo M, Yagishita S, Ihara Y, J Biol Chem 2008 283 19283 19292 10.1074/jbc.M705954200 18480063
127. Plasmalogens inhibit APP processing by directly affecting gamma-secretase activity in Alzheimer's disease. Rothhaar TL, Grosgen S, Haupenthal VJ, Burg VK, Hundsdorfer B, Mett J, Riemenschneider M, Grimm HS, Hartmann T, Grimm MO, ScientificWorldJournal 2012 2012 141240 22547976
128. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tschape JA, De Strooper B, Muller U, Shen J, Hartmann T, Nat Cell Biol 2005 7 1118 1123 10.1038/ncb1313 16227967
129. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP, Proc Natl Acad Sci U S A 2004 101 2070 2075 10.1073/pnas.0305799101 14970312 (Pubitemid 38229016)
130. Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase: implications for Alzheimer's disease. Jana A, Pahan K, J Biol Chem 2004 279 51451 51459 10.1074/jbc.M404635200 15452132 (Pubitemid 40017893)
131. Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, Chen S, Hsu CY, J Cell Biol 2004 164 123 131 10.1083/jcb.200307017 14709545 (Pubitemid 38082463)
132. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G, Neuron 2007 56 66 78 10.1016/j.neuron.2007.08.008 17920016 (Pubitemid 47484175)
133. Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. Tamboli IY, Prager K, Thal DR, Thelen KM, Dewachter I, Pietrzik CU, St George-Hyslop P, Sisodia SS, De Strooper B, Heneka MT, Filippov MA, Muller U, Van Leuven F, Lutjohann D, Walter J, J Neurosci 2008 28 12097 12106 10.1523/JNEUROSCI.2635-08.2008 19005074
134. Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Area-Gomez E, De Groof AJ, Boldogh I, Bird TD, Gibson GE, Koehler CM, Yu WH, Duff KE, Yaffe MP, Pon LA, Schon EA, Am J Pathol 2009 175 1810 1816 10.2353/ajpath.2009.090219 19834068
135. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, De Groof AJ, Madra M, Ikenouchi J, Umeda M, Bird TD, Sturley SL, Schon EA, Embo J 2012 31 4106 4123 10.1038/emboj.2012.202 22892566
136. Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Landman N, Jeong SY, Shin SY, Voronov SV, Serban G, Kang MS, Park MK, Di Paolo G, Chung S, Kim TW, Proc Natl Acad Sci U S A 2006 103 19524 19529 10.1073/pnas.0604954103 17158800 (Pubitemid 46026064)
137. The gamma-secretase inhibitor DAPT increases levels of gangliosides at neuritic terminals in differentiating PC12 cells. Oikawa N, Goto M, Ikeda K, Taguchi R, Yanagisawa K, Neurosci Lett 2012 525 49 53 10.1016/j.neulet.2012.07. 027 22867970
138. Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. Pierrot N, Tyteca D, D'Auria L, Dewachter I, Gailly P, Hendrickx A, Tasiaux B, Haylani LE, Muls N, N'Kuli F, Laquerriere A, Demoulin JB, Campion D, Brion JP, Courtoy PJ, Kienlen-Campard P, Octave JN, EMBO Mol Med 2013 5 608 625 10.1002/emmm.201202215 23554170
139. Accumulation of flotillin-1 in tangle-bearing neurones of Alzheimer's disease. Girardot N, Allinquant B, Langui D, Laquerriere A, Dubois B, Hauw JJ, Duyckaerts C, Neuropathol Appl Neurobiol 2003 29 451 461 10.1046/j.1365-2990. 2003.00479.x 14507337 (Pubitemid 37222719)
140. Paired helical filaments contain small amounts of cholesterol, phosphatidylcholine and sphingolipids. Gellermann GP, Appel TR, Davies P, Diekmann S, Biol Chem 2006 387 1267 1274 16972796 (Pubitemid 44402074)
141. Autophagy, amyloidogenesis and Alzheimer disease. Nixon RA, J Cell Sci 2007 120 4081 4091 10.1242/jcs.019265 18032783
142. Common and uncommon pathogenic cascades in lysosomal storage diseases. Vitner EB, Platt FM, Futerman AH, J Biol Chem 2010 285 20423 20427 10.1074/jbc.R110.134452 20430897
143. Lysosomal dysfunction in a mouse model of Sandhoff disease leads to accumulation of ganglioside-bound amyloid-beta peptide. Keilani S, Lun Y, Stevens AC, Williams HN, Sjoberg ER, Khanna R, Valenzano KJ, Checler F, Buxbaum JD, Yanagisawa K, Lockhart DJ, Wustman BA, Gandy S, J Neurosci 2012 32 5223 5236 10.1523/JNEUROSCI.4860-11.2012 22496568
144. Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Mansson JE, Porter FD, Blennow K, Neurology 2011 76 366 372 10.1212/WNL.0b013e318208f4ab 21205675